Research & News

Raltegravir and Pregnancy

Jan 30, 2015

Researchers looked at the pharmacokinetics of raltegravir for use as an antiretroviral during pregnancy.  Despite decreased rates of absorption during pregnancy, the drug readily crossed the placenta.  Similar decreases in rates in non pregnant adults indicates that... Read More

Meta-Analysis of Hormonal Contraception Use and HIV Risk

Jan 29, 2015

A meta-analysis of 12 studies showed an increased risk of HIV acquisition for women using Depo-Provera (depot medroxyprogesterone acetate) as birth control compared with women in the general population.  In addition, there was no increased risk for those women using oral... Read More

Next HIV-Specific Prenatal Classes Begin February 2015

Jan 29, 2015

The next series of PACPI's HIV-specific prenatal classes have been scheduled for February and March 2015.  Please see the attached flyer for the class and call 312-334-0971 to enroll your clients and patients.

Exposure In Utero to ARVs and Risk of Birth Defects

Jan 05, 2015

Researchers from the French Perinatal Cohort Study examined in utero exposure to antiretrovirals during the first trimester and whether this exposure resulted in birth defects.  Specifically, researchers determined that first trimester exposure to zidovudine resulted in... Read More

Raltegravir During Pregnancy

Dec 31, 2014

A study of the pharmacokinetics of raltegravir use during pregnancy showed that the medication, when taken twice daily as part of cART, readily crossed the placenta however the median raltegravir area under the curve was reduced by approximately 50% during pregnancy. ... Read More

PrEP for HIV Prevention and Hormonal Contraceptive Use

Dec 26, 2014

The efficacy of preexposure prophylaxis (PrEP) for HIV-1 prevention has been demonstrated amongst serodiscordant couples.  Researchers in this study wanted to determine that couples where the woman (whether HIV-negative or HIV-positive) used the hormonal contraceptive... Read More

Postpartum Antiretrovirals and HIV Transmission Through Breastfeeding

Dec 26, 2014

The Breastfeeding, Antiretrovirals, and Nutrition (BAN) study randomized mother-infant pairs post-delivery to determine whether 28 weeks of triple therapy (for the mother) or daily infant nevirapine was more effective in prevention of HIV transmission through... Read More

Very Early Treatment (VET) to Prevent Infant HIV

Dec 26, 2014

Researchers discuss the feasibility and limitations of very early treatment (VET) for infants perinatally infected with HIV-1, using the Mississippi child as the demonstration case.  VET is highlighted as a possibility for HIV remission for the pediatric population and... Read More

New Series of HIV-specific Prenatal Classes to Begin in January 2015

Dec 05, 2014

The next series of PACPI's HIV-specific prenatal classes have been scheduled for January 2015. Please see the attached flyer for the class and call 312-334-0971 to enroll your clients and patients.  

Intimate Partner Violence and Perinatal HIV Transmission

Nov 30, 2014

Diagnosis of HIV in women can trigger intimate partner violence (IPV) as issues of disclosure to her partner or accusations of unfaithfulness in the relationship arise. Researchers in South Africa found that women who were diagnosed HIV-positive during pregnancy may have... Read More